Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.
about
Inherited colorectal cancer syndromesHow do we approach the goal of identifying everybody with Lynch syndrome?Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized MedicinePredictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age.Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.The genetic basis of Lynch syndrome and its implications for clinical practice and risk management.Familial colon cancer syndromes: an update of a rapidly evolving fieldEvaluating genomic tests from bench to bedside: a practical frameworkHereditary cancer risk assessment: essential tools for a better approach.Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome.Barriers and motivators for referral of patients with suspected lynch syndrome to cancer genetic services: a qualitative studyFamilial colorectal cancer, beyond Lynch syndromeKnowledge, attitudes and referral patterns of lynch syndrome: a survey of clinicians in australiaRole of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer.The search for unaffected individuals with Lynch syndrome: do the ends justify the means?Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome.Communication and technology in genetic counseling for familial cancer.Comparative effectiveness of screening strategies for Lynch syndrome.A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients.The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening.Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online SampleDetecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness AnalysisIs the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing.Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.Influence of patient preferences on the cost-effectiveness of screening for lynch syndromeAchieving behaviour change for detection of Lynch syndrome using the Theoretical Domains Framework Implementation (TDFI) approach: a study protocolWhen is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping reviewComparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromesHigh risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.Elevated risk of prostate cancer among men with Lynch syndrome.Genetic screens to identify pathogenic gene variants in the common cancer predisposition Lynch syndrome.Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients.Adrenocortical carcinoma is a lynch syndrome-associated cancerPrediction models in Lynch syndrome.Chemoprevention of endometrial cancer in Lynch syndrome: a step forwardScreening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.
P2860
Q24628009-95256005-945B-40BA-AF63-98F3DB9A1337Q26865836-FC8FADF4-B476-4A1A-8205-23879B089784Q30513982-8ACFCDE3-F6C7-4062-B1B1-C44F01AF8600Q33775336-DF76072B-A9CA-475A-9D4A-0DD6A1AEA637Q33874719-51B7A13B-D019-438F-9998-0B895811990FQ34081267-A2C4C26F-55FA-4266-83B4-DBFDE9520A2CQ34292368-6F73A52A-DC10-4B51-886F-9B937CEE37A0Q34451291-5BD3BE5A-BD7D-4624-9085-49DADD198A14Q34507839-3DE0BB32-419E-415E-B274-6749D42D680BQ34543387-D3622989-6FED-4EDC-8BE7-672568A62D80Q34608805-5F3E91F8-C08D-4BC9-B5F3-9C5F1ACB2D46Q34655489-A7205008-6714-4D3B-8209-AED3FA5CCAD2Q34683932-678FFBBB-F63F-4865-B812-6A4EC6620B2AQ34785026-E12D2C9C-6552-4C68-A74E-9E15CAE137DBQ34792640-DAE43C4E-0198-4456-AC14-652A4FF1C097Q35168638-3E01D933-35DF-45D2-9D20-50B74CEB8B8BQ35212286-9C9B71A0-FB0B-4AA9-B003-FB51757A1B91Q35474031-8E96AD02-3ED5-409F-9141-8844A1A7D036Q35596050-D30214FE-D9C0-4F53-8411-030B4FE08C15Q35602902-ED9BE01E-E040-4ADB-B8ED-227681B7D5DFQ35681121-21C5420F-CC8F-48DC-A202-268019D21F0DQ35822142-DA901B58-7BBD-4B5D-BE88-FDC7AA108611Q35850612-0E737CDB-1620-432A-B61F-441FA0B0E9A0Q35916640-A9FD0EED-E965-4856-977E-6096111FD15DQ35925229-D7D051F5-9AF3-460D-8ACA-4DFD0C5C1E1DQ35925275-6214B323-9506-4890-B2E5-5BA9FD4767ABQ35947752-606D89F4-C8B0-43FC-83E3-77976511EF6FQ35954744-8D89CACE-D832-4B0A-A3D7-1A3F79E777A4Q36157315-4D944E6F-6854-434C-A437-E75EB9310276Q36304418-F84B6FEC-A63A-4EB0-8124-D01829C2C7F6Q36315747-78ACB580-4D49-4F73-96A9-2B0AF476C537Q36416282-FC4C09C7-1F0A-4882-B4EC-8EEFB5A09182Q36808349-7CC1C638-3A8C-4989-A249-C05691B09199Q36810712-83D70E30-1B92-439D-A874-40101C1870C7Q36915541-8DA5A7E5-E642-41DA-8843-93922C7CD481Q37053724-9B3F3D6C-F4B0-4ACC-9E01-FD559CB04897Q37085859-716B879A-DC3A-410B-9286-42324FF879B2Q37133163-5AFB2D25-544F-4F6A-85FD-C5C9E9E482D6Q37158268-C0A6B357-14F8-43BD-9E46-E1317830361EQ37160085-E0F1CFF3-7174-4EE7-874D-398C431A0610
P2860
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Health benefits and cost-effec ...... ome in the general population.
@en
Health benefits and cost-effec ...... ome in the general population.
@nl
type
label
Health benefits and cost-effec ...... ome in the general population.
@en
Health benefits and cost-effec ...... ome in the general population.
@nl
prefLabel
Health benefits and cost-effec ...... ome in the general population.
@en
Health benefits and cost-effec ...... ome in the general population.
@nl
P2093
P2860
P1476
Health benefits and cost-effec ...... rome in the general population
@en
P2093
Benjamin I Rosner
C Richard Boland
James C Atwood
Randall W Burt
Sapna Syngal
Stephen B Gruber
Tuan A Dinh
P2860
P356
10.1158/1940-6207.CAPR-10-0262
P50
P577
2010-11-18T00:00:00Z